Ask AI

The Next Frontier for CDK4/6 Inhibitors in Breast Cancer: Expert Strategies for Applying the Latest Guidelines and Advances in Practice

Enhance your ability to optimally integrate CDK4/6 inhibitors into practice based on current guidelines and expert-recommended best practices to improve outcomes of patients with breast cancer across the disease continuum through a certified on-demand webcast, downloadable slides, expert office hours online forum, and a ClinicalThought commentary.

Share

Program Content

Events

Activities

CDK4/6i in Breast Cancer ASCO Forum
ClinicalThought Expert Office Hours Forum: The Next Frontier for CDK4/6 Inhibitors in Breast Cancer - Applying the Latest Guidelines and Advances in Practice
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 15, 2026

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Decera Clinical Education

ProCE Banner